CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 23 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
Indications Brain metastases; Small cell lung cancer
Focus Therapeutic Use
Acronyms CASPIAN-RT

16 Oct 2023 Status changed from recruiting to withdrawn prior to enrolment.
19 Sep 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 11 Sep 2023 to 19 Oct 2023.
11 Aug 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 5 Aug 2023 to 11 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com